The effect of the putative endogenous imidazoline receptor ligand, clonidine-displacing substance, on insulin secretion from rat and human islets of Langerhans

British Journal of Pharmacology

Volumn 120, Issue 5, 1997, Pages 926-932

  Chan, Susan L F ^a   Atlas, Daphne ^b   James, Roger F L ^b   Morgan, Noel G ^c  

^a KEELE UNIVERSITY   (United Kingdom)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Endogenous ligand; I site; Imidazoline; Insulin secretion; Islets of Langerhans

Indexed keywords

2 (2,3 DIHYDRO 2 BENZOFURANYL) 2 IMIDAZOLINE; BRAIN EXTRACT; CLONIDINE DISPLACING SUBSTANCE; DIAZOXIDE; EFAROXAN; GLUCOSE; IMIDAZOLINE; IMIDAZOLINE RECEPTOR; INSULIN; KU 14R; LIGAND; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; INSULIN RELEASE; MALE; MOLECULAR WEIGHT; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BENZOFURANS; BRAIN; CLONIDINE; HUMANS; INSULIN; ISLETS OF LANGERHANS; LIGANDS; MALE; POTASSIUM; RATS; RATS, WISTAR; RECEPTORS, DRUG; SODIUM; YOHIMBINE;

EID: 0030895801     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0700964     Document Type: Article

References (48)

1. ATLAS, D. (1990). Clonidine-displacing substance (CDS) and its putative imidazoline receptor. Biochem. Pharmacol., 41, 1541-1549.
2. ATLAS, D. (1995). Molecular and physiological properties of clonidine-displacing substance. Ann. New York Acad. Sei., 763, 314-324.
3. ATLAS, D. & BURSTEIN, Y. (1984). Isolation of an endogenous clonidine-displacing substance from rat brain. FEBS. Lett., 170, 387-390.
4. ATLAS, D., DIAMANT, S., FALES, P.M. & PANNELL, L. (1987). The brain's own clonidine: purification and characterization of endogenous clonidine-displacing substance from brain. J. Cardiovasc. Pharmacol., 10, S122-S127.
5. BERRIDGE, T.L., DOXEY, J.C. & ROACH, A.G. (1992). Comparison of the effects of efaroxan and glibenclamide on plasma glucose and insulin levels in rats. Ear. J. Pharmacol., 213, 213-218.
6. BROWN, C.A., CHAN, S.L.F., STILLINGS, M.R., SMITH, S.A. & MORGAN, N.G. (1993a). Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline RX801080. Br. J. Pharmacol., 110, 1017-1022.
7. BROWN, CA., LOWETH, A.C., SMITH, S.A. & MORGAN, N.G. (1993b). Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding site. Br. J. Pharmacol., 108, 312-317.
8. 2-adrenoceptors and imidazoline binding sites in control of insulin secretion. Clin. Sei., 85, 671-677.
9. 2-adrenoceptor antagonist, efaroxan, involves a novel stereoselective binding site. Eur. J. Pharmacol., 230, 375-378.
10. 2-sites. Br. J. Pharmacol., 112, 1065-1070.
11. CHAN, S.L.F., CABLE, H.C. & MORGAN, N.G. (1995). Agmatine, a putative endogenous ligand at imidazoline binding sites, is a weak potentiator of insulin secretion. Pharmacol. Commun., 7, 29-41.
12. + -ATP channels in insulin secreting cells. Eur. J. Pharmacol., 204, 41-48.
13. CHAN, S.L.F. & MORGAN, N.G. (1990). Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Eur. J. Pharmacol., 176, 97-101.
14. DIAMANT, S. & ATLAS, D. (1986). An endogenous ligand substance, CDS (clonidine-displacing substance), inhibits the twitch response of rat vas deferens. Biochem. Biophys. Res. Commun., 134, 184-190.
15. 2-adrenoceptors of human platelets. Eur. J. Pharmacol., 144, 247-255.
16. DUNNE, M.J. (1991). Block of ATP-regulated potassium channels by phentolamine and other α-adrenoceptor antagonists. Br. J. Pharmacol., 103, 1847-1850.
17. DUNNE, M.J., HARDING, E.A., JAGGAR, J.H., SQUIRES, P.E., LIANG, R., KANE, C, JAMES, R.F.L. & LONDON, N.J. (1995). Potassium channels, imidazolines, and insulin-secreting cells. Ann. New York Acad. Sei., 763, 243-261.
18. ERNSBERGER, P., GRAVES, M.E., GRAFF, L.M., ZAKIEH, N., NGUYEN, P., COLLINS, L.A., WESTBROOKS, K.L. & JOHNSON, G.G. (1995). Ii-Imidazoline receptors. Definition, characterisation, distribution and transmembrane signalling. N. Y. Acad. Sei., 763, 22-42.
19. FELSEN, D., ERNSBERGER, P., MEELEY, M.P. & REIS, D.J. (1987). Clonidine-displacing substance is biologically active on smooth muscle. Eur. J. Pharmacol., 142, 453-455.
20. GEY, C.O. & GEY, M.K. (1936). Maintenance of human normal cells in continuous culture: preliminary report; cultivation of mesoblastic tumors and normal cells and notes on methods of cultivation. Am. J. Cancer, 27, 45-76.
21. HENSLEY, M.L., MEELEY, M.P., McCAULEY, P.M., ERNSBERGER, P. & REIS, D.J. (1989). Clonidine-displacing substance is present in peripheral tissues of the rat. Am. J. Hypertens., 2, 917-919.
22. ISMAIL, N.A., EL-DENSHARY, E.S.M., IDAHL, L.-A., LINDSTRÖM, P., SEHLIN, J. & TÄLJEDAL, I.-B. (1981). Effects of alphaadrenoceptor agonists and antagonists on insulin secretion, calcium uptake, and rubidium efflux in mouse pancreatic islets. Ada Physiol. Scand., 118, 167-174.
23. + channels in pancreatic B-cells. Br. J. Pharmacol., 107, 8-14.
24. 2-adrenoceptors and of non-adrenergic idazoxan binding sites in pancreatic islets from young and adult hamsters. Int. J. Biochem., 25,1077-1083.
25. LAKE, S.P., BASSETT, P.D., LARKINS, A., REVELL, J., WALCZAK, K., CHAMBERLAIN, J., RUMFORD, G.M., LONDON, N.J.M., VEITCH, P.S., BELL, P.R.F. & JAMES, R.F.L. (1989). Large scale purification of human islets utilizing discontinuous albumin gradients on IBM 2991 cell separator. Diabetes, 38 (Suppl. 1), 143-154.
26. LI, G., REGUNATHAN, S., BARROW, C.J., ESHRAGHI, J., COOPER, R. & REIS, D.J. (1994). Agmatine is an endogenous clonidine-displacing substance in brain. Science, 263, 966-969.
27. MEELEY, M.P., HENSLEY, M.L., ERNSBERGER, P., FELSEN, D. & ERNSBERGER, D.J. (1992). Evidence for a bioactive clonidinedisplacing substance in peripheral tissues and serum. Biochem. Pharmacol., 44, 733-740.
28. MICHEL, M.C. & ERNSBERGER, P. (1992). Keeping an eye on the I-site: imidazoline-preferring receptors. Trends Pharmacol. Sei., 13, 369-370.
29. MONTAGUE, W. & TAYLOR, K.W. (1968). Pentitols and insulin release by isolated rat islets of Langerhans. Biochem. J., 109, 333-339.
30. MORGAN, N.G., CHAN, S.L.F., BROWN, C.A. & TSOLI, E. (1995). Characterization of the imidazoline binding site involved in regulation of insulin secretion. Ann. New York Acad. Sei., 763, 361-373.
31. 2-Adrenoceptors modulating insulin release from isolated pancreatic islets. Natmyn-Schmiedeberg's Arch. Pharmacol., 313, 151-153.
32. 2 receptors. Eur. J. Pharmacol., 262, 41-48.
33. PALLETT, A.L., CHAN, S.L.F., RAMSDEN, C.A. & MORGAN, N.G. (1996). Effect of structural modifications on the insulin-secretagogue activity of efaroxan. Diabetic Med. (in press).
34. PINTHONG, D., WILSON, V.O. & KENDALL, D.A. (1995a). Comparison of the interaction of agmatine and crude methanolic extracts from bovine lung at aa-adrenoceptors on guinea-pig cortex slices. Br. J. Pharmacol., 116, 310P.
35. 2-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 351, 10-16.
36. + channels in mouse pancreatic B-cells. Br. J. Pharmacol., 101, 115-120.
37. REGUNATHAN, S., MEELEY, M.P. & REIS, D.J. (1991). Clonidine-desplacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells. Mol. Pharmacol., 40, 884-888.
38. REGUNATHAN, S. & REIS, D.J. (1996). Imidazoline receptors and their endogenous ligands. Ann. Rev. Pharmacol. Toxicol., 36, 511-544.
39. REIS, D.J., LI, G. & REGUNATHAN, S. (1995). Endogenous ligands of imidazoline receptors: classic and immunoreactive clonidine-displacing substance and agmatine. Ann. New York Acad. Sei., 763, 295-313.
40. REMAURY, A. & PARIS, D. (1992). The insulin-secreting cell line, RINmSF, expresses an alpha-D adrenoceptor and nonadrenergic idazoxan binding sites. J. Pharmacol. Exp. Ther., 260, 417-426.
41. 2-adrenoceptors are blocked. Naunyn-Schmiedeberg's Arch. Pharmacol., 340, 305-309.
42. SENER, A., LEBRUN, P., BLACHIER, F. & MALAISSE, W.J. (1989). Stimulus-secretion coupling of arginine-induced insulin release. Biochem. Pharmacol., 38, 327-330.
43. SINGH, G., HUSSAIN, J.F., MACKINNON, A., BROWN, CM., KENDALL, D.A. & WILSON, V.G. (1995). Evidence for the presence of a non-catecholamine, clonidine-displacing substance in crude, methanolic extracts of bovine brain and lung. NaunynSchmiedeberg's Arch. Pharmacol., 351, 17-26.
44. SMITH, P.K., KROHN, R.I., HERMANSON, G.T., MALLIA, A.K., GÄRTNER, F.H., PROVENZANO, M.D., FUJIMOTO, E.K., GOEKE, N.M., OLSON, B.J. & KLENK, D.C. (1985). Measurement of protein using bicinchoninic acid. Anal. Biochem., 150, 76-85.
45. SYNETOS, D., MANOLOPOULOS, V.O., ATLAS, D. & PIPILI-SYNETOS, E. (1991). Human plasma-derived material with clonidinedisplacing substance (CDS)-like properties contracts the isolated rat aorta. J.Auton. Pharmacol., 11, 343-351.
46. VIRSOLVY-VERGINE, A., BRÜCK, M., DUFOUR, M., CAUVIN, A., LUPO, B. & BATAILLE, D. (1988). An endogenous ligand for the central sulfonylurea receptor. FEBS Lett., 242, 65-69.
47. VIRSOLVY-VERGINE, A., LERAY, H., KUROKI, S., LUPO, B., DUFOUR, M. & BATAILLE D. (1992). Endosulfine, an endogenous peptidic ligand for the sulfonylurea receptor; purification and partial characterization from ovine brain. Proc. Nail. Acad. Sei. U.S.A., 89, 6629-6633.
48. VIRSOLVY-VERGINE, A., SALAZAR, G., SILLARD, R., DENOROY, L., MUTT, V. & BATAILLE, D. (1996). Endosulfine, endogenous ligand for the sulphonylurea receptor: isolation from porcine brain and partial structural determination of the ot form. Diabetologia, 39, 135-141.